Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs)
2023-510039-12-00Phase 4Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cabergoline in chromophobe adenoma (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Change in tumour volume over 2 years. Planned start Nov 2024; status: authorised.
02
Drugs
cabergoline
03
Conditions
chromophobe adenoma
Beyond the preview
Go deeper on 2023-510039-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510039-12-00.